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Background: About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with
unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC),
we investigated the presence and phenotypic features of Circulating Tumor Cells (CTC) in high-risk EC patients.
Methods: CTC isolation was carried out in peripheral blood samples from 34 patients, ranging from Grade 3 Stage
IB to Stage IV carcinomas and recurrences, and 27 healthy controls using two methodologies. Samples were
subjected to EpCAM-based immunoisolation using the CELLection™ Epithelial Enrich kit (Invitrogen, Dynal) followed
by RTqPCR analysis. The phenotypic determinants of endometrial CTC in terms of pathogenesis, hormone receptor
pathways, stem cell markers and epithelial to mesenchymal transition (EMT) drivers were asked. Kruskal-Wallis
analysis followed by Dunn’s post-test was used for comparisons between groups. Statistical significance was set
at p < 0.05.
Results: EpCAM-based immunoisolation positively detected CTC in high-risk endometrial cancer patients. CTC
characterization indicated a remarkable plasticity phenotype defined by the expression of the EMT markers ETV5,
NOTCH1, SNAI1, TGFB1, ZEB1 and ZEB2. In addition, the expression of ALDH and CD44 pointed to an association
with stemness, while the expression of CTNNB1, STS, GDF15, RELA, RUNX1, BRAF and PIK3CA suggested potential
therapeutic targets. We further recapitulated the EMT phenotype found in endometrial CTC through the
up-regulation of ETV5 in an EC cell line, and validated in an animal model of systemic dissemination the propensity
of these CTC in the accomplishment of metastasis.
Conclusions: Our results associate the presence of CTC with high-risk EC. Gene-expression profiling characterized a
CTC-plasticity phenotype with stemness and EMT features. We finally recapitulated this CTC-phenotype by
over-expressing ETV5 in the EC cell line Hec1A and demonstrated an advantage in the promotion of metastasis in
an in vivo mouse model of CTC dissemination and homing.
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Endometrial carcinomas, the most common tumors of
the female genital tract, are usually diagnosed at an early
stage with uterine-confined disease and an overall fa-
vorable prognosis. However, up to 20% of endometrial
carcinomas present as aggressive neoplasms such as
high-grade or deeply invasive lesions, at substantial risk
of recurrence and death [1]. Propagation of aggressive
tumor cells from the primary lesion is a key event in the
process of metastasis and a challenge in oncology. In
endometrial cancer, myometrial infiltration, lymph node
involvement, and lymphovascular space invasion are
current clinical parameters defining the probability of
recurrent disease. Nevertheless, early dissemination of
tumor cells is usually undetectable in patients by con-
ventional histopathological examination or by standard
imaging techniques. Recently, immunocytochemical and
molecular assays have been developed for the specific
detection of metastatic tumor cells at a cellular level in
lymph nodes, peripheral blood or bone marrow, prior to
the manifestation of metastasis. Tumor-cell dissemi-
nation can proceed at an early stage of tumor develop-
ment [2], and detecting circulating tumor cells (CTC)
has clinical value in the monitoring and the outcome of
metastatic disease. CTC analysis represents an attractive
candidate for liquid biopsy in cancer [3]. Clinically, the
presence of CTC above a threshold may have a signifi-
cant adverse impact on survival. Likewise, changes on
CTC quantification during treatment can reflect prog-
nostic significance, the future challenge being whether
treatment decision-making should be impacted by CTC
levels [4].
The increasing interest in CTC at the clinical setting is
resulting in the development of a number of innovative
technologies that include immunoenrichment, micro-
fluidics and filtration devices, combined with semiauto-
mated microscopy or PCR-based detection systems [5].
We have recently demonstrated that the combination of
CTC EpCAM-based immunoisolation, followed by ac-
curate extraction and pre-amplification of RNA from
very small number of CTC, provided with a highly sen-
sitive approach to profiling the metastatic tumor cell
population in a group of colorectal cancer patients [6].
In the present study, we adopted a similar approach in
high-risk EC patients. CTC immunoisolation plus pro-
filing of a number of genes related to key events in the
process of metastasis in EC provided us with an over-
view of the biology of endometrial CTC. In addition to
analyze in immunoisolated CTC the expression of a
number of genes involved in signaling pathways related
to EC, hormone pathways, stem cell features and epi-
thelial to mesenchymal transition (EMT) markers, we
evaluated the efficiency of CTC quantification and its
correlation with clinical parameters.Results
Assessment of CTC in the blood samples from high-risk
EC patients
Immunoisolation of CTC from peripheral blood samples
has been performed with magnetic beads coated with
EpCAM antibodies. We thus first confirmed the posi-
tivity for EpCAM expression in the corresponding pri-
mary carcinomas of a representative sample of patients
included in the study (Figure 1A). Secondly, we investi-
gated the presence and quantified the amounts of CTC
in a series of 34 EC patients ranging from Grade 3 Stage
IB carcinomas to metastatic Stage IV carcinomas and re-
currences (see global clinical descriptions in Table 1).
CTC were immunoisolated with EpCAM-dynabeads
from EDTA-BD Vacutainer 7.5 ml blood collection tube.
Upon RNA extraction and pre-amplification, we eva-
luated the expression levels of GAPDH as a marker of
cellularity, which includes both CTC and unspecific
blood cells, normalized to the background of CD45 ex-
pression as specific marker for cells of hematopoietic
origin [7]. As shown, GAPDH levels were significantly
higher in the group of patients compared to controls
(Figure 1B; with 30 high-risk EC patients below control
upper threshold and 3 controls above lower patients’
threshold), while CD45 did not present differences bet-
ween both groups (Figure 1C), indicating (i) the pre-
sence of an extra population of cells isolated from the
blood of high-risk EC patients and (ii) the unspecific
background resulting from the process of immunoisola-
tion was similar in the group of patients and controls.
The presence of CTC in high-risk endometrial cancer
patients was further confirmed with the technology that
received to date Food and Drug Administration (FDA)
clearance for the monitoring of metastatic breast, colorec-
tal, and prostate cancer, the CellSearch System (Janssen
Diagnostics, SouthRaritan, NJ, USA), which combines im-
munoenrichment and immunofluorescence for the de-
tection of CTC [8-10] (Additional file 1). Globally, these
results demonstrated in parallel the presence of CTC in
high-risk EC patients.
Gene-expression analysis in immunoisolated CTC from EC
patients highlights a plasticity phenotype
Once we confirmed their presence, we explored the gene-
expression profile of CTC in the samples from high-risk
EC patients upon EpCAM-based immunoisolation and
RNA extraction and pre-amplification. For this, we
analyzed genes of signaling pathways previously reported
to be related to EC (BRAF, CTNNB1, ERBB2, FGFR2,
GDF15, IDO, MTOR, P53, PIK3CA, PTEN, PTGS2,
RUNX1, RELA, STMN1, TERT, VIL1, ZWINT), hormone
pathways (CYP19, ESR1, ESR2, GPER, HSD17B1, PGR,
STS, TFF1), stem cell features (ALDH, CD133, CD44), and
EMT related markers (ETV5, LOXL2, NOTCH1, SNAI1,
Table 1 Clinical and pathologic characteristics of high-risk EC patients included in the gene-expression profiling of CTC
Feature n (%) Feature n (%)
Age (years)
Mean 69
FIGO Stage Lymphovascular invasion
I 15 (44.15) Positive 6 (17.6)
II 2 (5.8) Negative 15 (44.1)
III 11 (32.35) Unknown 13 (38.2)
IV 6 (17.64) Lymph node metastasis
Histology Positive 12 (35.3)
Endometrioid 19 (55.9) Negative 20 (58.8)
Serous 10 (29.4) Unknown 2 (5.9)
Clear cell 5 (14.7) Recurrence
Grade No 18 (52.9)
Well differentiated (G1) 4 (11.8) Yes 15 (44.1)
Moderately differentiated (G2) 6 (17.6) Unknown 1 (2.9)
Poorly differentiated (G3) 21 (61.8) First treatment
Unknown 3 (8.8) Radiotherapy 4 (11.8)
Myometrial invasion Chemotherapy 7 (20.6)
<50% 13 (38.2) None 17 (50)
>50% 18 (52.9) Unknown 6 (17.6)
Unknown 3 (8.8)
Unknown values were considered as missing and therefore excluded from the statistical analysis.
Figure 1 Immunoisolation of CTC in high-risk EC patients. (A) Representative primary carcinoma of a patient included in the study, demonstrating
positivity for membrane EpCAM staining in epithelial tumor cells. (B) GAPDH expression levels normalized to CD45 in CTC isolated from the group
of controls (white box, n = 27), as background of unspecific immunoisolation, and from the group of high-risk EC patients (grey box, n = 34)
(Mann–Whitney test, ***p < 0.001). (C) CD45 expression levels in CTC isolated from controls and patients; similar expression denoted equivalent
degree of unspecific immunoisolation.
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a preliminary set of 6 patients and 6 controls no amplified
signal could be observed either in patients or in controls
probably due to non-detectable levels of expression, genes
were excluded from further evaluation. This primary
screen resulted in exclusion of CD133, GPER, HSD17B1,
PGR, and TERT (data not shown).
We next analyzed the expression levels of the re-
maining genes in the whole set of patients and controls,
and identified those genes with a significant expression
in CTC from the group of patients compared to the
background of unspecific isolation from the controls.
These genes are considered to characterize the popula-
tion of CTC in EC. We further grouped those high-risk
patients presenting FIGO Stages I-II and those with
FIGO Stages III-IV and recurrences, as stages presenting
no or local cell tumor spread and those presenting
systemic dissemination, respectively. Overall, major sig-
nificances were found between the group of healthy con-
trols and FIGO Stages III-IV and recurrences, consistent
with a gradual increased presence of CTC as the disease
disseminates; modest increases in a reduced number of
genes in FIGO Stages I-II that might suggest the pre-
sence of CTC in early stages has to be interpreted
with caution due to the limited number of patients
(Figure 2A).Figure 2 Gene expression profiling in endometrial CTC. (A) Significant
altered in EC, (B) hormone pathways and (C) stem cell features, in CTC from
immunoisolation. White boxes represent the gene expression levels in the
FIGO Stages I and II EC patients while dark grey boxes those corresponding
*p < 0.05; **p < 0.01; ***p < 0.001).Among genes related to EC pathogenesis, we found sta-
tistical increased expression in the group of Stage III-IV
carcinomas and recurrences compared with healthy
controls for BRAF, for the Wnt pathway component
CTNNB1, for the TGF-beta superfamily cytokine GDF15,
for PIK3CA, for NF-κB family member RELA, and for the
RUNX transcription factor family member RUNX1,
(Figure 2A). Regarding genes from hormone pathways, we
found a significant increased expression of STS in ad-
vanced stage cases compared with controls (Figure 2B).
Increased expression in both ALDH and CD44 as genes
related to stem cell features was observed in CTC immu-
noisolated from Stages III and IV high-risk EC patients
and recurrences compared with controls (Figure 2C). The
correlation between the levels of expression of these can-
didate biomarkers and the clinicopathological features of
patients included in the study, indicated that the expres-
sion of BRAF, PIK3CA, RELA, RUNX1 (all involved in
endometrial carcinogenesis) and CD44 (stem cell marker)
was increased in CTC isolated from patients with the
tumor infiltrating more than 50% of the myometrium
(n = 18) compared with those isolated from patients
having myometrial invasion below 50% of the myome-
trium (n = 13) (Additional file 3).
More interestingly, almost the complete set of genes
associated with EMT (ETV5, NOTCH1, SNAI1, TGFB1,expression levels of genes involved in signaling pathways reported
high-risk EC patients compared to the background of unspecific
group of healthy controls, light grey boxes those corresponding to
to FIGO Stages III-IV EC patients and recurrences. (Kruskal-Wallis test,
Alonso-Alconada et al. Molecular Cancer 2014, 13:223 Page 5 of 10
http://www.molecular-cancer.com/content/13/1/223ZEB1 and ZEB2) were found to be specifically expressed
in CTC from EC patients when compared to unspecific
background from controls (Figure 3), with LOXL2
achieving a value close to significance (p = 0.08; data not
shown). We also found statistical increased expression
levels in the EMT marker ZEB2, together with RUNX1,
when we compared high-risk EC patients presenting re-
currences (n = 15) or not (n = 18) (Additional file 3).
Likewise, when we assessed the panel of CTC signifi-
cantly expressed genes in a small series of matched pri-
mary endometrial carcinomas and affected lymph nodes
(n = 6), the expression of the EMT related gene ZEB2
demonstrated the best performance among a global ten-
dency for an increased expression in lymph node metas-
tasis compared to primary lesions, (p = 0.09; Additional
file 4). No significant differences were found for any spe-
cific histology subtype regarding EMT markers, but we
cannot exclude whether this could be due to the limited
number of samples in the study or to the absence of dif-
ferences in disseminated disease. We are currently in-
creasing the number of paired matched samples in order
to confirm these data. Overall, gene profiling on CTC
isolated from high-risk EC patients suggested a plasticity
phenotype characterized by genes of stem cell features
and EMT, with potential in the clinical management of
high-risk EC patients.
ETV5 recapitulates the EMT phenotype characterizing CTC
and impacts metastasis in an EC mouse model
ETV5 transcription factor, one of the candidate genes
characterizing the CTC-plasticity phenotype, plays a
major role in EC as a regulator of EMT [11,12]. This led
us to further asses the role of ETV5 in endometrial CTC
and evaluate whether the invasive phenotype promoted
by ETV5 during myometrial infiltration recapitulated
the CTC phenotype observed in patients. To this end,
the naïve EC cell line Hec1A and the cell line Hec1A
over-expressing ETV5 were used. As can be observed inFigure 3 Plasticity phenotype characterizes CTC in EC. Almost all gene
significant expression compared to the background of unspecific immunoi
of healthy controls, light grey boxes those corresponding to FIGO Stages I
Stages III-IV EC patients and recurrences. (Kruskal-Wallis test, *p < 0.05; **p <Figure 4A, an increase in ETV5 expression resulted in
the concomitant up-regulation of genes related to EMT,
as observed in CTC. These results suggested that at least
part of the plasticity phenotype observed in CTC in EC
patients might be associated with the up-regulation of
ETV5 during myometrial invasion and confirmed the
role of ETV5 as a master regulator of EMT.
We further investigated the impact of ETV5 up-
regulation and the consequent EMT phenotype in a
mice model that reproduced the systemic dissemination,
homing and generation of micrometastasis associated
with CTC. For this, we compared the extent of metasta-
sis resulting from the intracardiac injection of both naïve
Hec1A cells (Figure 4B, upper panels), and ETV5 over-
expressing Hec1A cells (Figure 4B, lower panels), further
modified to constitutively express the luciferase reporter
gene and allow vital bioluminescent imaging of dis-
seminating tumor cells. As shown in Figure 4B, the up-
regulation of ETV5 and the consequent recapitulation of
the CTC-plasticity phenotype resulted in a more dra-
matic cell dissemination and metastatic spread, both in
terms of pattern of metastasis localization as well as the
number of metastasis foci (Figure 4C, D). In addition to
reinforce the role of ETV5 during the initial events of
metastasis in endometrial cancer, these results link the
promotion of a plasticity phenotype in CTC with their
capacity to metastasize.
Discussion
We present in this study evidences for the presence of
CTC in high-risk EC patients, and further characterized
a molecular CTC-phenotype associated with plasticity
and stemness features. The major clinical relevance of
CTC is that the early detection in patients could be of
use for the identification of candidate subjects needing
additional systemic therapies after the resection of the
primary tumor. Although the aim of these therapies is
the prevention of metastasis, the selection of patients iss related to EMT assessed in CTC from high-risk EC patients presented
solation. White boxes represent the gene expression levels in the group
and II EC patients while dark grey boxes those corresponding to FIGO
0.01; ***p < 0.001).
Figure 4 ETV5 recapitulates the EMT phenotype found in CTC
and the metastasis potential in an EC mouse model. (A) CTC-gene
expression profiling in Hec1A and Hec1A-ETV5 cell lines by RT-qPCR.
The results were represented as the fold change in gene expression
relative to GAPDH gene expression (2-ΔΔCt). (B) Representative
luminiscence examples of athymic nude mice inoculated with Hec1A
(upper panels) or Hec1A-ETV5 (lower panels) cells by intracardiac
injection. Luminescence images were acquired for 1 min at ventral
(left image) and dorsal (right image) positions. (C) Extent of
dissemination evaluated as number of metastasis and (D) as
luminescence quantification of metastasis.
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which is not accurate in terms of over-treatment of pa-
tients with toxic agents or therapeutic procedures caus-
ing serious side effects, in addition to economic costs.
An improved ability to target surgical and systemic the-
rapies to well selected high-risk patient populations will
increase the likelihood of benefits and decrease the sideeffects associated with un-necessary treatments [13]. In
addition, the sequential assessment of CTC levels during
treatment could provide information at early stages
about the therapeutic efficacy of drugs. Likewise, the
elimination of these CTC could represent an inter-
mediate endpoint in clinical trials with antitumor drugs.
Furthermore, the molecular and functional characte-
rization of CTC will be determinant in the discovery of
new molecular tumor markers and in the development
of therapies specific for the process of tumor dissemi-
nation and metastasis. Overall, CTC represent a potent
and promising tool in oncology and, although the cli-
nical role of CTC as a prognosis factor is being recog-
nized, there is still a need for more advanced and precise
techniques of detection and robust clinic-pathologic cor-
relations [14].
From our results, we can conclude that EpCAM-based
immune-enrichment followed by RT-qPCR analysis is a
reliable method to effectively isolate CTC from high-risk
EC patients and to potentially distinguish high-risk from
low-risk patients. Previous efforts to analyze and evaluate
CTC in EC included the assessment of a six gene panel in
blood samples [15]. Although this methodology represents
a semi-quantitative evaluation of CTC, it demonstrated an
added value compared to the gold standard CellSearch
technology for the positive detection of CTC (see
Additional file 1). In addition to the clinical utility of CTC
as a surrogate marker in the management of high-risk and
metastatic cancer patients, the challenge stands on the
possibility of a therapeutic approach targeting these meta-
static CTC with the aim of controlling and/or eradicating
the source of recurrences. The advantage of combining
CTC immunoisolation and RT-qPCR analysis consists in
the possibility to identify and characterize biomarkers spe-
cific of this subpopulation of metastatic cells. This ap-
proach has the limitation to determine whether the
increased levels in biomarker expression upon CTC
immunoisolation is related to an enhanced expression or
to an augmentation in the number of CTC. Nevertheless,
in addition to their potential in terms of diagnosis/progno-
sis and follow-up of patients, these biomarkers provide
with phenotypic clues on the biology of CTC that may be
determinant in the identification of new therapeutic strat-
egies aiming to specifically control and/or eradicate the
metastatic dissemination in EC [16]. From a clinical per-
spective, the management of metastatic EC has been
recently considered as a poly-chemotherapy adjuvant regi-
men for patients with high risk of relapse, and as a pal-
liative regimen for patients with disseminated disease or
with extrapelvic recurrence not responding to hormone
treatment. In addition, endometrial carcinomas are
considered as chemoresistant and the most active drugs
(platinum salts, doxorubicin, anthracyclines and pacli-
taxel) present relative rate responses ranging from 25% in
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survival of 12–15 months. In this scenario, chemotherapy
has shown limited utility and there is a clear need for the
development of new rationale therapies focused on metas-
tasis [17]. To this regard, our profiling of endometrial
CTC has pointed out at a number of pathways relevant to
the metastatic process and that could be targeted. For in-
stance, the expression of STS, which is associated with
higher availability of estrogens in tumor cells [18], can
provide a growth advantage to CTC and its inhibition can
be used to block such event and decrease the risk of recur-
rences. A second important marker highly expressed in
CTC was PIK3CA, which confirms the role of this kinase
pathway as a potential target in high-risk and metastatic
disease [19-21].
A main feature observed in the molecular profiling of
CTC in EC corresponded to the EMT phenotype, with
almost all analyzed genes related to plasticity being sig-
nificantly expressed in CTC (ETV5, NOTCH1, SNAI1,
TGFB1, ZEB1, ZEB2). EMT is a dynamic process
whereby epithelial cells lose polarity and cell-cell con-
tacts, undergo dramatic remodeling of the cytoskeleton,
acquire a migratory phenotype and a mesenchymal-like
gene expression program. Both invasion and metastasis
may be critically dependent on the acquisition by the in-
cipient cancer cell of EMT features [22,23]. Interestingly,
both EMT and the PIK3CA pathway have been closely
linked in the promotion of metastasis, particularly in EC
[24,25]. Our results also reinforce a role for ETV5 in the
process of EMT and EC dissemination [11]. ETV5 up-
regulation in Hec1A cells recapitulated in vitro the
plasticity phenotype found in high-risk patients, and
demonstrated an advantage in the promotion of metas-
tasis in an in vivo mouse model that mimic CTC dis-
semination and homing.
Likewise, and concerning ALDH and CD44 as stem-cell
genes identified in this profiling, we observed a concor-
dance between the presence of endometrial CTC and
recurrent disease. Whether these CTC include a subpo-
pulation of tumor cells with a stem cell-like phenotype
(Cancer Initiating Cells [26]) or whole CTC population
must be considered responsible for recurrences with more
or less efficiency, has yet to be addressed. In addition to
its plasticity phenotype, CTC triggering micrometastasis
in the target organs must own the capacity to survive in
the blood flow, to home and to regenerate a tumor mass
with similar characteristics as the primary lesion in the tis-
sue recipient of metastasis. Recent studies on CTC in
breast cancer have demonstrated that a subset of isolated
CTC express stem cell markers such as those analysed in
our study [27,28]. The evidence that tumor dissemination
to the blood circulation is an early event and that the
process of metastasis is an ineffective process with only a
small number of CTC ending up in micrometastasis,support the hypothesis of a CTC phenotype with plasticity
and stemness features with the capacity to develop metas-
tasis [29]. This concept linking EMTand stem cell features
in the process of tumor dissemination has also been ad-
dressed in EC [30], in association with a micro-RNA sig-
nature of EMT in endometrial carcinosarcoma mainly
represented by the down-regulation of members of the
miR-200 family [31]. Remarkably, the balanced expression
of ZEB factors and miR-200 is considered as a molecular
motor of cellular plasticity, in particular is a driving force
for cancer progression towards metastasis by controlling
the state of cancer stem cells [32,33]. The results we ob-
tained both in CTC and in paired carcinoma and lymph-
node tissue samples demonstrating the potency of ZEB2
within the CTC-phenotype reinforce the need of future
investigations examining stem-like features in CTC to ob-
tain relevant information about this cancer subpopulation
responsible of metastases.
Finally, it should be note that although EpCAM ex-
pression was found consistent in primary endometrial
carcinomas, its proposed modulation and eventual loss
during EMT adds controversy to the efficiency of en-
richment of CTC owning a plasticity phenotype [34]. To
this regard, we analyzed the expression of EpCAM both
in the epithelial endometrial cancer cell line HEC1A
and its mesenchymal counterpart Hec1A-ETV5, and
found similar levels of EpCAM expression irrespective
of their EMT phenotype (Additional file 5). Moreover,
EpCAM-based immunoisolation of these HEC1A and
HEC1A-ETV5 cells lines rendered similar efficiencies
(75% versus 64%, respectively). From these results, it
seems reasonable to speculate that cells detaching from
the primary lesion and incorporating into the blood
stream recapitulate a metastable epithelial–mesenchy-
mal phenotype that may be maintained during their way
to those distant sites where this CTC will home and end
up in the generation of micrometastasis. The dis-
sociation of tumor cells from the epithelial layer and the
penetration through the basement membrane into the
adjacent connective tissue, are the initial events in the
multistep process that characterizes metastasis [35]. We
are additionally conducting further studies with other
immunoisolating antigens.
Conclusions
We present evidences for the presence of CTC in high-
risk EC patients, and we propose a CTC-phenotype in
EC associated with plasticity and stem cell features. Al-
though this multicentre study conducted within the
framework of ENITEC has the limitation of the number
of samples, these promising data offer the opportunity
to design new therapeutic strategies targeting metastatic
disease, and a larger prospective study is aimed for the
validation of the CTC-phenotype in high-risk EC.
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Patient samples
Peripheral blood samples collected just before initiation of
treatment from 34 EC patients and 27 controls were proc-
essed for CTC immunoisolation and accurate RNA extrac-
tion as described [7]. Patients participating in the study
were surgically staged according to FIGO and recruited
between March 2012 - October 2013 in Vall d’Hebron Uni-
versity Hospital (Barcelona, Spain), University Hospital of
Santiago de Compostela (Santiago de Compostela, Spain),
Arnau de Vilanova Hospital (Lleida, Spain), MD-Anderson
Cancer Center Madrid (Madrid, Spain), Fundacion Dexeus
(Barcelona, Spain) and Haukeland University Hospital
(Bergen, Norway), and included high-risk endometrial car-
cinomas ranging from Grade 3 Stage IB carcinomas to
metastatic Stage IV carcinomas and recurrences (Table 1).
Control group included a set of 27 healthy women with ab-
sence of a previous cancer episode and with an age range
similar to patients. Informed consent approved by the
relevant ethical committee was signed by all patients.
In addition, fresh-frozen tissue from primary tumor and
paired affected lymphatic nodes from 6 EC patients were
provided by Tumor Bank of the Vall d’Hebron University
Hospital Biobank (Barcelona, Spain) with appropriate
ethics approval.
EpCAM immunohistochemistry
EpCAM expression was checked in whole paraffin-
embedded sections of primary endometrial carcinomas
from patients prospectively subjected to evaluation of
CTC. Sections were dried for 1 h at 65°C before pre-
treatment procedure of deparaffinization, rehydration
and epitope retrieval in the Pre-Treatment Module,
PT-LINK (DAKO) at 95°C for 20 min in Citrate buffer
(10 mM), Low pH, endogenous peroxidase was blocked
before staining with antibodies against Epithelial Related
Antigen (clone MOC-31, dil. 1:50; DAKO, Denmark).
After incubation, the reaction was visualized with the
EnVision FLEX Detection Kit (DAKO) using diamino-
benzidine chromogen as a substrate.
Positivity ranged from 75% to 100% with a mean of
93%.
CTC immunoisolation and quantitative real-time
polymerase chain reaction (RT-qPCR)
CTC immunoisolation with the CELLection™ Epithelial En-
rich kit (Invitrogen, Dynal, Oslo, Norway), RNA extraction
and RT-qPCR were carried out as previously described [7].
After EpCAM-based immune-enrichment of CTC follo-
wing manufacturer’s protocol, RNA purification was per-
formed with QiampViral kit (Qiagen, Valencia, CA, USA),
optimized for very low cellularity samples. cDNA was
synthesized using SuperScriptIII chemistry (Invitrogen,
Carlsbad, CA, USA) according to the user’s guide andsubjected to pre-amplification with TaqMan®PreAmp
Master Mix kit (Applied Biosystems, Foster City, CA, USA)
for 14 reaction cycles before proceeding to RTqPCR,
to provide with optimal detection rates. TaqMan Gene
Expression Assays (Applied Biosystems, Foster City, CA,
USA) for 35 selected genes (Additional file 2; plus GAPDH
as housekeeping gene and CD45 as a marker of non-
specific isolation) were used to measure the gene ex-
pression levels in CTC isolated from patients in comparison
to the background of hematogenous cells unspecifically
immunoisolated from the group of healthy controls. Values
were analyzed using StepOne Software v.2.1 (Applied
Biosystems, Foster City, CA, USA), normalized to CD45
and represented as (40–ΔCt), whereby ΔCt = duplicate
mean (CtTARGET – CtCD45).Cell lines and cell culture
The human endometrial carcinoma cell lines Hec1A
and Hec1A stably expressing the ETV5 transcription
factor (Hec1A-ETV5) were maintained in McCoy’s 5A
Medium (Gibco, Grand Island, NY, USA) supplemented
with 10% FBS and 1% penicillin-streptomycin at 37°C in
5% CO2, Hec1A-ETV5 cells further selected with
Geneticin (500 μg/ml; Gibco, Grand Island, NY, USA).
These cells were previously generated and thoroughly
characterized [11,12].
To monitor non-invasively tumor grafts of Hec1A and
Hec1A-ETV5 cells, these cells were infected with lenti-
viruses bearing pLenti CMV V5-LUC Blast (w567-1)
(Addgene, Cambridge, MA, USA) to constitutively ex-
press the luciferase reporter gene, as previously de-
scribed [36]. Stable infected cells expressing luciferase
were selected with Blasticidine S HCl (3 μg/ml; Invitro-
gen, CA, USA).RNA extraction and real-time PCR
Paired frozen tumors and metastatic lymph node samples
were disrupted and homogenized using a TissueLyser II
(Qiagen, Valencia, CA, USA) and total RNA was extracted
using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
protocol. Alternatively, total RNA was isolated from
Hec1A and Hec1A-ETV5 cells using High Pure RNA
Isolation Kit (Roche Applied Science, Indianapolis, IN,
USA) according to the manufacturer.
cDNA synthesis was carried out using MuLV reverse
transcriptase Kit (Applied Biosystems, Foster City, CA,
USA) following the instructions provided by the manu-
facturer. Real-time PCR was performed using Applied
Biosystem 7500 Real-Time PCR Machine and data
were analyzed with StepOne Software v.2.1 (Applied
Biosystems, Foster City, CA, USA). GAPDH was used
as an internal normalization control. The results were
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to GAPDH gene expression (2-ΔΔCt).
In vivo assay and bioluminescent imaging
Six Five-week-old female athymic Nude-Foxn1nu mice
were purchased from Harlan Laboratories (Indianapolis,
IN). Mice were divided in 2 groups and either Hec1A or
Hec1A-ETV5 stably expressing luciferase cells (5×105 cells
in 100 μl of sterile PBS) were inoculated into animals by
intracardiac injection under 2% isoflurane/air anesthesia.
A successful intracardiac injection was indicated on day 0
by images showing systemic bioluminescence distributed
throughout the animal. Only mice with evidence of a satis-
factory injection continued in the experiment. Three
weeks after cells injection and before sacrifice, IVIS system
(Xenogen Corporation) coupled to Living Imaging soft-
ware 4.2 (Xenogen Corporation) were used to detect
tumor metastases by bioluminescent imaging. For non-
invasive bioluminescence tumour imaging, luciferin
(Firefly Luciferin, Caliper Lifescience Corp, Hopkinton,
MA, USA) was used as the substrate for the luciferase
expressing tumor cells and injected intraperitoneally at a
concentration of 150 mg/kg in PBS. Mice were housed
and maintained under specific pathogen-free conditions
and used in accordance with institutional guidelines ap-
proved by the Use Committee for Animal Care.
Statistical analysis
Statistical analyses were conducted using SPSS (Chicago,
version 15.00 for Windows) and GraphPad Prism 4.00
software (GraphPad Softwares Inc, San Diego, CA, USA).
Mann–Whitney and Kruskal-Wallis non-parametric tests
were used to determine the differences between con-
ditions. For Kruskal-Wallis analysis we used Dunn’s post-
test. Alternatively, Wilcoxon signed test was used to
determine the differences in relative gene expression bet-
ween paired frozen tumors and metastatic lymph node
samples. Statistical significance was set at p < 0.05.
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compared to primary lesions further reinforced the EMT phenotype in
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Additional file 5: EpCAM expression assessed in Hec1A and
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